<DOC>
	<DOCNO>NCT00748839</DOCNO>
	<brief_summary>Although Heparin-induced thrombocytopenia ( HIT ) rare complication heparin treatment , result high rate morbidity mortality , cumulative rate thrombosis recurrence , amputation death approach 52 % one month specific treatment initiate . It therefore vital diagnose HIT early reliably possible permit appropriate management rare condition . During acute phase HIT , clinicians biologist suspect complication great less degree confidence . Clinical data sufficiently sensitive specific confirm refute thr diagnosis HIT .</brief_summary>
	<brief_title>Heparin-Induced Thrombocytopenia : Development Validation Predictive Clinical</brief_title>
	<detailed_description>Purpose : To create validate score predict diagnosis HIT</detailed_description>
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Thrombocytopenia</mesh_term>
	<mesh_term>Calcium heparin</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<criteria>patient present , either immediately treatment : thrombocytopenia and/or venous arterial thrombosis request biological assessment check HIT ( antiHPF4 ELISA test ) address specialized haemostasis laboratory participate study posse sufficient clinical data prior performance biological test assure followup patient normalization platelet count</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>HIT</keyword>
	<keyword>Heparin-induced thrombocytopenia</keyword>
	<keyword>heparin treatment</keyword>
	<keyword>venous thrombosis</keyword>
	<keyword>arterial thrombosis</keyword>
	<keyword>predictive clinical score</keyword>
	<keyword>biological test</keyword>
	<keyword>anti-H-PF4 antibody</keyword>
</DOC>